Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Accenture
Harvard Business School
Medtronic
Chubb
Chinese Patent Office
Johnson and Johnson
Julphar
Argus Health

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022511

« Back to Dashboard

NDA 022511 describes VIMOVO, which is a drug marketed by Horizon Pharma Usa and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug and one Paragraph IV challenge. Additional details are available on the VIMOVO profile page.

The generic ingredient in VIMOVO is esomeprazole magnesium; naproxen. There are seventy drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the esomeprazole magnesium; naproxen profile page.
Summary for 022511
Tradename:VIMOVO
Applicant:Horizon Pharma Usa
Ingredient:esomeprazole magnesium; naproxen
Patents:14
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 022511
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511 NDA Horizon Pharma Inc. 75987-030 N 75987-030-73
VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511 NDA Horizon Pharma Inc. 75987-030 N 75987-030-04

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrengthEQ 20MG BASE;500MG
Approval Date:Apr 30, 2010TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Jul 6, 2020
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Patent:➤ Sign UpPatent Expiration:Nov 25, 2018Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:Feb 28, 2023Product Flag?YSubstance Flag?Delist Request?
Patented Use:RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

Expired US Patents for NDA 022511

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 ➤ Sign Up ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 ➤ Sign Up ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 ➤ Sign Up ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Farmers Insurance
Federal Trade Commission
AstraZeneca
Moodys
Colorcon
Citi
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.